Squar Milner Financial Services LLC raised its stake in Becton Dickinson and Co (NYSE:BDX) by 11.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,932 shares of the medical instruments supplier’s stock after acquiring an additional 201 shares during the period. Squar Milner Financial Services LLC’s holdings in Becton Dickinson and were worth $488,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. TRUE Private Wealth Advisors purchased a new stake in shares of Becton Dickinson and in the second quarter worth $25,000. Allworth Financial LP grew its stake in shares of Becton Dickinson and by 386.4% in the third quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 85 shares during the last quarter. Hexavest Inc. purchased a new stake in shares of Becton Dickinson and in the second quarter worth $28,000. Lipe & Dalton purchased a new stake in shares of Becton Dickinson and in the second quarter worth $28,000. Finally, CX Institutional bought a new position in shares of Becton Dickinson and during the third quarter valued at $31,000. 84.26% of the stock is currently owned by hedge funds and other institutional investors.
In other Becton Dickinson and news, SVP Charles R. Bodner sold 1,514 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.08, for a total value of $393,761.12. Following the transaction, the senior vice president now owns 5,180 shares of the company’s stock, valued at $1,347,214.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP James C. Lim sold 9,299 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $263.53, for a total value of $2,450,565.47. Following the completion of the transaction, the executive vice president now directly owns 33,041 shares in the company, valued at approximately $8,707,294.73. The disclosure for this sale can be found here. In the last three months, insiders sold 37,249 shares of company stock worth $9,616,803. 0.12% of the stock is owned by corporate insiders.
Shares of NYSE:BDX traded up $1.06 during midday trading on Wednesday, reaching $251.34. 584,893 shares of the company’s stock traded hands, compared to its average volume of 917,113. The company has a market cap of $68.60 billion, a price-to-earnings ratio of 22.83, a P/E/G ratio of 1.63 and a beta of 1.12. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $264.74. The stock has a 50 day moving average of $254.41 and a 200 day moving average of $246.27.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The firm had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same period in the prior year, the company posted $2.91 earnings per share. The company’s quarterly revenue was up 1.7% on a year-over-year basis. Sell-side analysts predict that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.
A number of research analysts have recently issued reports on BDX shares. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Piper Jaffray Companies lowered their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Wells Fargo & Co upped their price target on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, September 6th. Morgan Stanley upped their price target on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. Finally, Raymond James upped their price target on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a report on Friday, June 28th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $266.55.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: Return on Equity (ROE)
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.